Mirum Pharmaceuticals, Inc. (MIRM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Company Overview - Mirum Pharmaceuticals is focused on rare diseases and has three approved medicines projected to generate revenue between $490 million and $510 million this year, indicating a strong growth trajectory in its commercial business [4]. Pipeline Developments - The company recently announced the completion of enrollment for the VISTAS Phase IIb study of Volixibat for Primary Sclerosing Cholangitis (PSC), which is one of three potentially pivotal studies expected over the next 18 months, with top-line data anticipated in the second quarter of next year [4]. - Additionally, there is a follow-up indication for Volixibat in primary biliary cholangitis and a label expansion opportunity for LIVMARLI with the EXPAND study [4].